SCHEMBL20547285

SCHEMBL20547285

CCOC(=O)N1CCc2noc(-c3cccc(Cl)c3)c2CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.56
CYP3A4 P08684 3/20 0.48
GRM5 P41594 2/20 0.48
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 1/20 0.42
HTT P42858 1/20 0.42
TP53 P04637 2/20 0.42
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 2/20 0.41
CACNA1F O60840 1/20 0.41
NR1I2 O75469 1/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20547359 0.89 DPP4 (0.48) KCNH2CYP3A4GRM5SMN1; SMN2CYP1A2
SCHEMBL20547288 0.88 LMNA (0.50) KCNH2CYP3A4GRM5SMN1; SMN2HTT
SCHEMBL20547362 0.87 SMN1; SMN2 (0.53) KCNH2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL20547218 0.87 KMT2A (0.51) NPC1RAB9AL3MBTL1KMT2AMEN1
SCHEMBL20546709 0.82 LMNA (0.51) CYP2D6CYP2C9CYP2C19SMN1; SMN2CYP1A2
SCHEMBL20547246 0.81 NPC1 (0.53) SMN1; SMN2NPC1RAB9AL3MBTL1KMT2A
SCHEMBL20547217 0.81 LMNA (0.47) KCNH2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL20547293 0.78 NPC1 (0.54) SMN1; SMN2NPC1RAB9AL3MBTL1KMT2A
SCHEMBL20547245 0.77 NPC1 (0.53) KCNH2CYP3A4CYP2C9CYP2C19SMN1; SMN2
SCHEMBL22449874 0.74 ALDH1A1 (0.43) CYP2C9SMN1; SMN2TP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3560927-B1 AZEPINE DERIVATIVES ACTING AS 5-HT7 RECEPTOR MODULATORS KOREA INST SCI & TECH (KR) 2023-04-19 EP disclosed
EP-3560927-A1 AZEPINE DERIVATIVE ACTING AS 5-HT7 RECEPTOR MODULATOR Korea Institute of Science and Technology (KR) 2019-10-30 EP disclosed
US-10435408-B2 Azepine derivatives as 5-HT7 receptor modulators KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2019-10-08 US disclosed
US-20180312509-A1 AZEPINE DERIVATIVES AS 5-HT7 RECEPTOR MODULATORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312509-A1 AZEPINE DERIVATIVES AS 5-HT7 RECEPTOR MODULATORS HTR7, HTR5A, HTR3A KCNH2 918/4885CYP3A4 800/4885GRM5 31/4885
US-10435408-B2 Azepine derivatives as 5-HT7 receptor modulators HTR7, HTR5A, HTR3A KCNH2 918/4885CYP3A4 800/4885GRM5 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.